Conversely, the inhibition of OCT2 might protect patients from nephrotoxicity and ototoxicity induced by platinum derivatives and the inhibition of OCT3 from doxorubicin-induced cardiotoxicity without reducing their antitumor properties, as both OCT1 and OCT3 are poorly expressed in cancer cells [29,52]. The gene discussed is SLC22A2; the disease is cancer.